Trial Profile
A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Dynamics Following Administration of MK-5172 in Hepatitis C Infected Patients.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Grazoprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 26 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Aug 2014 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 15 Aug 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.